Physician profile
Marcos E Machado
NPI 1770515637
$1,807.19
in general payments reported to CMS, 2019-2025
20 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $129 · 2021: $152 · 2022: $305 · 2023: $379 · 2024: $299 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $212.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $186.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $138.92 | 2022-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $134.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $66.97 | 2019-2024 | Breztri |
| Dexcom, INC. | $40.09 | 2019-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $32.74 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $31.31 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $29.64 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Shire North American Group INC | $23.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.06 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $22.17 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $20.79 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.08 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $14.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.89 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $13.86 | 2021 | |
| Ibsa Pharma INC. | $13.54 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Machado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.